Addiction Science & Clinical Practice
February 4, 2026
Maya Appley, Jessica R Gray, Dima Abdulrahim et al.
1 citation
Non-medical ketamine use is becoming increasingly common in the United States (US), but awareness remains limited among US healthcare providers. Here we present the case of a young woman who developed severe ketamine use disorder in the setting of an acute exacerbation of chronic post-traumatic stress disorder (PTSD). She also demonstrated symptoms concerning for two known complications of...
Indian Journal of Psychiatry
February 1, 2026
Mahak Aggarwal, Jawahar Singh, Khushpreet Kaur et al.
Major depressive disorder and co-morbid substance use disorder represent a challenging dual diagnosis, characterized by persistent anhedonia, high relapse rates, and poor response to conventional antidepressants. The dextromethorphan-bupropion combination with synergistic glutamatergic and dopaminergic mechanisms provides a new treatment option. We present three male patients with alcohol or...
Quality in Sport
January 26, 2026
Adam Wolski, Ewa Szplit, Mikołaj Franciszek Patalong et al.
Background: Psychedelic substances have been used for millennia in religious and healing contexts and have recently re-emerged as subjects of scientific interest due to advances in neuroscience and psychiatry. Research suggests that psychedelics may address limitations of conventional psychiatric treatments, particularly in disorders such as major depressive disorder, PTSD, substance use...
International Journal of Innovative Technologies in Social Science
January 23, 2026
Jakub Klepacz, Radosław Swędrak, Marzena Swojnóg et al.
The escalating global burden of mental health disorders, coupled with the stagnation of innovation in traditional monoaminergic pharmacotherapy (e.g., SSRIs), has precipitated a critical need for novel therapeutic paradigms. This article presents a comprehensive systematic review of the so-called "Psychedelic Renaissance," focusing on the clinical resurgence of classical serotonergic...
Psychopharmakotherapie
2026
Antonia Bendau, Felix Betzler, Twyla Michnevich et al.
1 citation
Party drugs encompass a broad spectrum of legal and illegal psychoactive substances used in party settings such as clubs, festivals, raves or private gatherings to modulate mood, perception, social interaction and bodily states. Most commonly, alcohol and cannabis are consumed, followed by amphetamine, MDMA (“ecstasy”), cocaine and ketamine. Synthetic cathinones, GHB/GBL (“liquid ecstasy”),...
Transportation research procedia
2026
Samuel Hubočan, Matúš Madleňák
Safety and security in traffic is a fundamental need of every road user. There are many factors that have a direct impact on this need. It can be assumed that vehicle driving competencies represent one of these factors. A vehicle driver should be vigilant, decisive and capable of practical use of traffic rules implied by the legal system. Addictive substances can disrupt driver’s capabilities...
Journal of Clinical Medicine
December 29, 2025
Monika Dominiak, Adam Gędek, Szymon Modrzejewski et al.
2 citations
Background: Psychedelic-assisted therapy is gaining renewed attention as a potential treatment for various mental disorders. Despite increasing numbers of randomized controlled trials (RCTs) and meta-analyses, a comprehensive synthesis of the evidence across different substances and indications is lacking. This umbrella review aims to evaluate the effectiveness and safety of...
Psychiatry Research
December 29, 2025
Omer A. Syed, Sean M. Nestor, Muhammad Ishrat Husain et al.
1 citation
Psychedelic use has greatly increased within clinical and recreational settings over recent years. While demonstrating a favorable safety profile within certain clinical populations, little empirical research has explored safety of psychedelic use within real-world samples. Using the World Health Organization (WHO) VigiBase, a comprehensive global pharmacovigilance database with voluntary...
Theoretical and Natural Science
December 24, 2025
Yiyin Hu
Ketamine is a traditional anesthetic, which has attracted much attention in recent years for its rapid antidepressant effect. It has performed particularly well in the treatment of patients with intractable depression, marking major breakthrough in the area of mental illness treatment. However, with further research, its potential neurotoxicity has gradually emerged, especially in the case of...
Psychedelic Medicine
December 19, 2025
Amanda Husein, Madalynn Traylor, M. Frances Vest et al.
Background: Psilocybin has been granted breakthrough therapy status in the United States, speeding its advancement from research to clinical care. Due to the controversial nature of psilocybin, psychiatrists may not be fully prepared to incorporate it into clinical practice. The current study aimed to evaluate the opinions toward psilocybin among practicing psychiatrists in Louisiana. Louisiana...